High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival

BACKGROUND: High tumor mutation burden is shown to be associated with a poor clinical outcome. As the tumor‐derived fraction of circulating cell‐free DNA (cfDNA) is shown to reflect the genetic spectrum of the tumor, we examined whether the mutation burden of cfDNA could be used to predict the clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Kujala, Jouni, Hartikainen, Jaana M., Tengström, Maria, Sironen, Reijo, Kosma, Veli‐Matti, Mannermaa, Arto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433819/
https://www.ncbi.nlm.nih.gov/pubmed/32602248
http://dx.doi.org/10.1002/cam4.3258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433819/
https://www.ncbi.nlm.nih.gov/pubmed/32602248
http://dx.doi.org/10.1002/cam4.3258

Ejemplares similares